Introduction
Current treatment modalities for patients with glioma are surgery, radiotherapy, and chemotherapy. Advances in these therapies extended the prognosis tor patients with low-grade glioma from 5 years to lO years ove~ the time period of 1984·1995 (I). However, the progn<Jsis for patients with high·grade glioma, especially with gliobbstomn multiformc (GBM) , remains less than I year (2·4). To improve the prognosis for patients with GBM, it is crucial to explore novd therapeulic modalities.
Recently, we have reported that the transduction of the Fas associated protein with death domain (FADD) gene effectively induces apoptos is in h urn an ma I ig nant g 1 io m a cells (5). The FADD gene is a down-stream death sign;JJ for the apoptosis pathway of Fas/ AP0-1, a transmembrane receptor for tumor necrosis factor a (TNFa) (6-lO) . There are several reports demonstrating the effectiveness of the treatment with Fas ligand for cancer cells with Fas/APO-l (II-13). However, Pas ligand does not lead cells to apoptosis unless the target cells express Fas/APO·I, as shown in some malignant glioma cell lines (5). In contrast. the FADD gene transfer induces cell death regardless of the expression of Fas/ APO-i in the target cells, indicating high potential in cancer gene therapy (5). Nevertheless. a major drawback of the FADD gene therapy is that the FADD gene can cause cell death not only in malignant cells but ;~lso in normal brain cei!s.
To overcome this problem, we developed a gene transfer system under the control of the human telomcrase reverse transcriptase (hTERT) promoter (14) . This system enables us to restrict transfer of the thcmpeutic gene to those cells which have telomerasc activity, because telomerase activity is lightly regulated at the transcriptional level of hTERT (15, 16) . We hypothesized that FADD gene transfer under the control of the hTERT promoter (hTERT/FADD) might induce apoptosis only in telomcrase-posilivc malignant glioma cells while keeping telomerase-negative normal cells intact. The fact that a vast rnnjority of GI3Ms has telomcrase nctivity while norm;;~! human brain tissues lack the enzyme (17) (18) (19) (20) (21) makes hTERT/ FADD a very attract ive and promising strategy to target tclomcrasc-positive malignant gliomas.
In the present study, we developed PADD gene tnmsfcr system under the control of the hTERT pmmoter. Then. we investigated whether the hTERT/FADD construct successfully induces the expression of FADD, resulting in induction of apoptosis in hTERT-positivc hunn. , malignant glioma cells.
It is or gccat importance to observe if normal cells without hTERT remain intact or not with this stmtegy.
Materials and methods
Cef/5. Human malignant gli')llla U373-MG, Al72 cells ::~nd human fibroblnst MRCS cells were purchased from ATCC (American Tissue Culture Collection, Rockville, MD). Human malignant gl ioma GB-1 cells were kindly gifted by Dr Tatsuo Mori mura (National Uta no Hospital, Kyoto, 1 apan). Cells were cultured in DMEM (Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (Gibco 13RL). 4 mM glutamine, 100 U/ml penicillin and 100 ~tg/ml streptomycin. Human astrocyte TEN cells were kindly gifted by Dr Barbara P. 13arna (Mctrohealth Medical Center, Cleveland, OJ-I), and maintained in RPMJ 1640 medium (Gibco BRL) supplemented with lOr!!; fetal bovine serum (Gibco I3RL), 4 mM glutamine, 100 Ufml penicillin and iOO j.tg/ml streptomycin.
RT.PCR analysis fori!TERT.
The expression of hTERT mRNA w:~s <malyzed hy semi-quantitative RT-PCR amplification as recently described (22) . The correlation between band intensity and dose of eDNA templates was linear under the conditions described below. RNA of ench cell line was isolated using the RNA Isolation Kit (Stratagene, La Jolla, CA). RT-PCR was performed with total RNA (0.1 J.tg) using the ProStarTM First Strand RT-PCR Kit (Stratagene, La Jolla, CA). The thermal cycles were: 94'C for I min, 60'C for 2 min, and 70"C for 2 min for 35 cycles for GAPDH (450 bp), 94"C for I min, s:rc for I min, 72"C for I min for 37 cycles for hTERT (145 bp). The primer sets used were as follows (23) : GAPDH, 5'-CTCAGACACCATGGGGAAGGTGA-3' (forward) and 5'-ATGATC'l1'GAGGCTGTTGTCAT A-3' (reverse); hTERT, 5'-CGGAAGAGTGTCTGGAGCAA-3' (forward) and 5'-GG ATGAAGCGGAGTCTGGA-3' (reverse). The amplified products were fractionated on a 2% agarose gel comaining 0.5 ~tg/ml ethidium bromide, gels were photographed with Polnroid film (Polaroid type 667), and photographs were quantitatively scanned using the NIH image software. The amount of eDNA synthesis from each sample was estimated by PCR with GAPDI I-spccific primers , Lucifer(l.\"e assay. Transcriptional acti vily of hTERT in normal or tumor cells was determined by the luciferase reporter plnsmids as described previously (24, 25) . Cells were plated at a density of l.Ox.i0
5 cells/ml I dny prior to transfection of the lucifcrasc reporter plasmicls. Cells were washed anJ the media w-:~s replaced with OPTI-MEM (Gibco RRL) and trnnsfected by using Lipofectamine (Gibco BRL) as previously (26) . Pony-eight hours after transfection. cells were washed twice with PBS and lysed in the lysis buffer provided with the luciferasc kit (Promega Corp.-BTC, Madison, WI). Lucifcrase activity was measured using a Microliter Plate Luminometer (Dynatech Laboratories, Jnc., Chantilly, VA). The following plasmids were used: the hTERT promoter plasmid (pGL3 -!81), the negative control without promoter (pGL3-basic). and the positive control with SV40 enhancer/promoter (pGL3-control) as described previously (25) . The !uciferase activity of the pGL3-basic plasmid in each cell line was considered as 1.0 .
Cmwmcrion of the hTERT promoter plasmid carrying FADD gene. To construct the FADD expression vectors under hTERT promoter, the hTERT promoter-luciferase (pGL3-18l) construct was used as described previously (25) . The vector including the full length coding region of FADD (pcDNA3~ AU l-FADD) (6) was a generous gift from Dr Vishva M. Dixit (University of Michigan, Ann Arbor, MI) and used as a template. The 712 bp fragment of FADD was generated by PCR amplicnting with 5'-GAAAGATCTGTCGACACGTG-3' and 5'-ACAGCAGATCTGGATCCAG-3'. The PCR amplified product was then ligated into Bg/II-Xbal site of pGL3 181 instead of Juciferase, and designated as lhc hTERT/FADD expression vector.
Transient tramjectio11 assay. Transient transfection assays by
Lipofcctamine·mediated gene transfer (Gibcn) were performed as described previously (5,26,27). Co-trnnsfection of 11-galactosidase gene plasmid (Promega Corp.-BTC) was performed to detect transfectcd cells. One day before transfection, cells were seeded at 10 5 cells/ml in Lab-Tek chamber slides. The hTERT/FADD construct (I J.tg) together with 1.\-galactosidase pl<tsmid (0.5 ~tg) were trnnsfccted into cells, and incubated for 48 h. The hTERT/Iucife1asc construct was used as a negative control. To detect transfccled tumor cells, cells were fixed with I% formaldehyde and 0.2% glutuntldchyde for 5 min, rinsed with PBS, and incubated with X-Gal buffer [0.4 mg/ ml 5-hromo-4-chloro-3-indoxyl 13-galactosidase, 4 mM K 3 Fe(CN)~, 4 mM K 4 Fe(CNk3H 2 0, 2 mM MgCIL in 0.1 M sodium phosphate buffer (pi-I 7.5)] at 37"C for overnight. Cells were visualized by phase-contrast microscopy to detect morphological alterations typical of adhe1 ent cells undergoing apoptosis, such as round-shape cells or condensed nuclei as described previously (5,27,28). Apoptotic index was determined as a percentage of npoptotic cells among 100 X· Gal-positive cells.
Effect of FADD expressi0111111der rhe hTERT promoter in t>ivo.
Human glioma U373-MG cells (I. Ox 10 6 cells in 0.05 ml serum-free DMEM and 0.05 ml Matrig.:!l) \ver..: inu.:ulilted subcutaneously into the right flank of 8 to 12-week-old male Balb/c nude mice (6 mice for each treatment group) as described previously (29) . Tumor growth was monitored using calipers every other day. Tumor volume (V) was calculated as showed normal morphology for adherent cells, spindle shape, both in U373-MG and MRC5 cells (Fig. 313 , a and c) . With the hTERT/FADD construct, however, mnny cells with X-Galpositi ve staining showed rounded, condensed shape which is characleristic with apoptnsis in U373-MG cells while MRC5 cells re-mained intact {Fig. 3B, band d, respectively). Ap0ptofk morphology in UJ73-MG cells was mnfirmcd with Hoechst 33258 staining of lhc nuclei (data not shown). Furthermore, transfeclion with hTERT/FADD was perfi"xrncd on two more malignant glioma cell lines and cultured astrocytcs to confirm that the cytolox ic effect depends on the expression of hTERT of Ihc cell. Percenlage of apoptotic cells in X-0:11-positive cells were 26.6, 23.6, 47 .2, 4.0 and 0.0 for U373-MG, Al72, GI3-I, TEN and MRCS cells, respectively (Fig. 3C) . These data show that the hTERT/FADD conslruct induced apoptos is in a significant port ion of trans fected cells.
It should be emphasized that apoptotic cell death took place selectively in hTERT-positive malignant glioma cells. but not hTERT-negative cells.
Effect of the lt'f"ERTIFADD treatment on tumor cefls ill vivo.
Since (Fig. 4A) . The treatment with the hTERT/FADD construct inhibited tumor growth significantly (p=0.0001). Slices of the removed tumors were stained to detect apoptosis or the FADD protein.
As shown in Fig. 4B , the tumor tTeated with the hTERT/FADD construct showed TUNEL-positive, apoptotic cells (Fig . 4B, b ) while few positive stained cells were detected in the control tumor (Fig. 4B) . Immunohistochemical reactivity again~L FADD antibody was detected only in the tumor trentcd with the hTERTIFADD con~truct. These results indicate that the anti -tumor effect of the hTERT/FADD construct was mainly due to apoptosis induced by FADD expression.
Discussion
We have demonstrated that the FADD gene was successfully and specifically expressed in hTERT-posilive malignant glioma cells using the hTBRT promoter system. Apoptos1s was induced in transl'ected malignant glioma cells while hTERTnegative fibroblasts and astrocytes were spared . The in vitro studies revealed apoptosis in significant portion of malignant glioma cells after the transfection with the hTERT/FADD construct. Twenty-four to 4 7% of trans fee ted cc ll s in malignant glioma cells showed apoptotic morphology 48 h after transfection . Since the assay was performed only at one time po int, the cxtenl of cell death was underestimated due to the following reasons. Cells which died within 48 h after transfeclion might h;~ve been already detached from the culture plnte and could not be detected . And there might be more cells induced to die more than 48 h after transfection. Therefore, to estimate what percentage of transfected cells actually die, we may need to detect apoptolic cells at many time points. Furthermore, the hTERT/FADD consti'UCt significantly inhibited tumor growth in vivo, due to induction of apoptosis, at !cast in part. Staining of tumor samples for 'fUNEL and FADD was only for one time point, which is after a 7-day treatment. Although anim:1.ls arc athymic, nude mice still possess macrophages and microglia in the immune sy~lem. It is possible that tumor cells which underwent apoptosis within 7 days after the initiation of the treatment might have been phagocytosed and/or removed. To examine this possibility, we may need to monitor the extent of cell death during the whole course of the treatment.
Tclomerase is an RNA-protein complex which plays an important role in cancer cells. Development of a PCR-based assay to detect telomerase activity made it convenient to screen tissue samples for te!omernse activity . A vast majmity of malignant gliomas express the enzyme. The incidence of telomerase activity in GBMs for three different studies on a large group of 40 or more tumors ranges from 72.3 to 89(/f; (17, 18, 30) . On the contrary, normal brain tissues clo not have telomerase except for early fetal period (20.21) . Therefore, this exclusive expression of telomerase in malignant glioma makes the hTERT/FADD system theoretically attractive as a nove! targeted therapy. There arc some reports utilizing the promoter of hTERT to kill tumor cells selectively. Cytotox ic genes used to induce apoptosis were caspa5e-8 (14) , BAX (31 ) , and re v-caspase-6 (32). These studies showed that the therapeutic gene was successfully expressed in targeted tumor cells and killed them effectively. It is of interest to investigate which of these genes or FADD used in this study has the strongest effect or whether they work to a similar extent against tumor growth.
Engelhard classified gene therapy strategies against cancer into 5 categories: i) gene-directed enzyme prodrug (suicide gene) therapy; ii) gene therapy designed to boost the activity of the immune system against cancer cells; iii) oncolytic virus therapy; iv} transfer of potentially therapeutic genes into cancer cells; and v) antisense therapy (33) . The present study belongs lo the fourth category, transfer of therapeutic genes. One of the most challenging issues toward a clinical trial is to increase transduction efficacy of the therapeutic genes. In order to improve the efficacy, continuous deli very using an osmotic pump, mkrosphere or polymer may be useful particularly for malignant brain tumors. In conclusion, the present study demonstrated that the FADD gene transfer using the hTERT promoter was successful in expressing the FADD prote in and inducing apoptosis in hTERT-positive malignant glioma cells. On the other hand, not·mal cells lacking hTERT were spared from ce II death. Si nee antitumor effect was observed also in the animal model, the hTERT/FADD construct may become a promising novel therapy against malignant gliomas.
